APT(SH:688617) Ge Long Hui·2026-02-26 09:29Core Viewpoint - Huatai Medical (688617.SH) reported a significant increase in both revenue and net profit for the fiscal year 2025, indicating strong operational performance and effective market strategies [1] Financial Performance - The company achieved an operating revenue of 2.584 billion yuan, representing a year-on-year growth of 25.08% [1] - The net profit attributable to the parent company was 821 million yuan, reflecting a year-on-year increase of 21.91% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 791 million yuan, with a year-on-year growth of 23.00% [1] Operational Drivers - Key factors influencing operational performance included the company's ongoing market expansion efforts and various promotional activities [1] - The company leveraged its strengths in R&D, technology, quality, market, and channels to enhance product coverage and hospital admission rates [1] - Focused cost control measures were implemented, with R&D and sales expenses concentrated on core products like PFA, ensuring synchronized growth of net profit and revenue through optimized spending [1]